# cbdMD, Inc.: overview YCBD · NYSE · CIK 1644903 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/ycbd.md) · [Financials](/companies/ycbd/financials.md) · [Filings](/companies/ycbd/filings.md) · [Insiders](/companies/ycbd/insiders.md) Latest reported revenue: [$5.6m](/filings/0001437749-26-027665.md) for Q3 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001437749-26-027665). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [4,556 d](/filings/0001437749-25-038435.md) | [5,113](/filings/0001437749-26-004343.md) | [4,749](/filings/0001437749-26-017042.md) | [4,607](/filings/0001437749-26-027665.md) | [4,721 d](/filings/0001437749-25-038435.md) | [5,017](/filings/0001437749-26-004343.md) | [5,640](/filings/0001437749-26-017042.md) | [5,554](/filings/0001437749-26-027665.md) | | Gross margin | % | [53.9% d](/filings/0001437749-25-038435.md) | [66.5%](/filings/0001437749-26-004343.md) | [62.3%](/filings/0001437749-26-017042.md) | [61.5%](/filings/0001437749-26-027665.md) | [58.8% d](/filings/0001437749-25-038435.md) | [59.8%](/filings/0001437749-26-004343.md) | [57.7%](/filings/0001437749-26-017042.md) | [54.7%](/filings/0001437749-26-027665.md) | | Operating margin | % | [(6.9%) d](/filings/0001437749-25-038435.md) | [(1.7%)](/filings/0001437749-26-004343.md) | [(10.2%)](/filings/0001437749-26-017042.md) | [(19.6%)](/filings/0001437749-26-027665.md) | [(14.5%) d](/filings/0001437749-25-038435.md) | [(5.7%)](/filings/0001437749-26-004343.md) | [(14.2%)](/filings/0001437749-26-017042.md) | [(20.4%)](/filings/0001437749-26-027665.md) | | Net margin | % | [(3.4%) d](/filings/0001437749-24-037840.md) | [0.3%](/filings/0001437749-26-004343.md) | [(10.1%)](/filings/0001437749-26-017042.md) | [(19.4%)](/filings/0001437749-26-027665.md) | [(14.4%) d](/filings/0001437749-25-038435.md) | [(5.6%)](/filings/0001437749-26-004343.md) | [(14.1%)](/filings/0001437749-26-017042.md) | [(20.3%)](/filings/0001437749-26-027665.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $k | [157 d](/filings/0001437749-25-038435.md) | [(482)](/filings/0001437749-26-004343.md) | [(205) d](/filings/0001437749-26-017042.md) | [(706) d](/filings/0001437749-26-027665.md) | [(244) d](/filings/0001437749-25-038435.md) | [(977)](/filings/0001437749-26-004343.md) | [(728) d](/filings/0001437749-26-017042.md) | [(460) d](/filings/0001437749-26-027665.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [44.5](/filings/0001437749-22-029136.md) | [35.4](/filings/0001437749-23-035228.md) | [24.2](/filings/0001437749-24-037840.md) | [19.5](/filings/0001437749-25-038435.md) | [19.2](/filings/0001437749-25-038435.md) | | Gross margin | % | [67.4%](/filings/0001437749-22-029136.md) | [63.1%](/filings/0001437749-23-035228.md) | [62.0%](/filings/0001437749-24-037840.md) | [61.6%](/filings/0001437749-25-038435.md) | [62.4%](/filings/0001437749-25-038435.md) | | Operating margin | % | [(44.1%)](/filings/0001437749-22-029136.md) | [(221.1%)](/filings/0001437749-23-035228.md) | [(93.1%)](/filings/0001437749-24-037840.md) | [(17.0%)](/filings/0001437749-25-038435.md) | [(11.3%)](/filings/0001437749-25-038435.md) | | Net margin | % | [(52.6%)](/filings/0001437749-22-029136.md) | [(198.0%)](/filings/0001437749-23-035228.md) | [(95.0%)](/filings/0001437749-24-037840.md) | [(19.0%)](/filings/0001437749-25-038435.md) | [(10.6%)](/filings/0001437749-25-038435.md) | | Diluted EPS | $ per share | [(0.47)](/filings/0001437749-22-029136.md) | [(55.80)](/filings/0001437749-23-035228.md) | [(13.32)](/filings/0001437749-24-037840.md) | [(14.29)](/filings/0001437749-25-038435.md) | [(1.09)](/filings/0001437749-25-038435.md) | | Free cash flow | $m | [(14.4)](/filings/0001437749-22-029136.md) | [(15.7)](/filings/0001437749-23-035228.md) | [(4.6)](/filings/0001437749-24-037840.md) | [(0.5)](/filings/0001437749-25-038435.md) | [(1.6)](/filings/0001437749-25-038435.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ycbd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Worth Venture Partners, LLC](/funds/1696778.md) | 2026-06-30 | $124.4k | 184,796 | | Unchanged | | [CSS LLC/IL](/funds/1103646.md) | 2026-06-30 | $92.6k | 137,621 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $80.5k | 119,645 | | Added +68,592 | | [CHAPIN DAVIS, INC.](/funds/872098.md) | 2026-06-30 | $54.7k | 81,250 | | Unchanged | | [Alesco Advisors, LLC, An ESL Co](/funds/1269978.md) | 2026-06-30 | $46.1k | 68,513 | | Unchanged | | [Chicago Partners Investment Group LLC](/funds/1563525.md) | 2026-06-30 | $45.0k | 78,098 | | Added +64,598 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $42.2k | 62,743 | | Reduced −29,306 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $36.6k | 54,401 | | Reduced −21,937 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $31.7k | 47,157 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $14.5k | 21,576 | | Reduced −143,067 | ## Recent filings [All 535 filings](/companies/ycbd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-02 | 07:30 ET | [8-K](/filings/0001437749-26-029455.md) | 1.01 Entry into a material agreement; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-029455 | | 2026-08-13 | 16:06 ET | [10-Q](/filings/0001437749-26-027665.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027665 | | 2026-05-20 | 17:16 ET | [8-K](/filings/0001437749-26-017970.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001437749-26-017970 | | 2026-05-14 | 16:06 ET | [10-Q](/filings/0001437749-26-017042.md) | Quarterly report, period 2026-03-31 | 0001437749-26-017042 | | 2026-04-15 | 16:15 ET | [8-K](/filings/0001437749-26-012392.md) | 8.01 Other events | 0001437749-26-012392 | | 2026-04-01 | 16:05 ET | [8-K](/filings/0001437749-26-010878.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-010878 | | 2026-02-20 | 19:53 ET | [S-1/A](/filings/0001437749-26-004777.md) | Registration statement, amended | 0001437749-26-004777 | | 2026-02-17 | 16:06 ET | [10-Q](/filings/0001437749-26-004343.md) | Quarterly report, period 2025-12-31 | 0001437749-26-004343 | | 2026-02-12 | 17:36 ET | [DEF 14A](/filings/0001437749-26-003831.md) | Proxy statement, period 2026-03-30 | 0001437749-26-003831 | | 2026-01-22 | 09:14 ET | [S-1](/filings/0001437749-26-001692.md) | Registration statement | 0001437749-26-001692 | ## Latest annual report [Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001437749-25-038435.md), filed Dec 19, 2025. ## Forecast league Q4 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/72a69b95-ea71-4ddf-920a-12616601db2c) ## About the filer - CIK: 1644903 - Tickers: YCBD - Exchange: NYSE - SIC code: 2844 Perfumes, Cosmetics & Other Toilet Preparations - State of incorporation: NC - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.